Heightened hygiene is critical for aviation as COVID intensifies
The sudden resurgence of COVID outbreaks, including the virulent Delta strain, and the rapid and increasing reintroduction of restrictions in Australia and New Zealand, have reinforced the importance of robust hygiene protocols for airlines and airports.
Lockdowns of Sydney, Darwin, Perth, Brisbane, Gold Coast, Cairns and Townsville, plus the recent shutdown of Melbourne, and the suspension of the successful trans-Tasman travel bubble, have all impacted heavily on economic and social transactions within and between both countries.
The Australia-New Zealand travel bubble, one of the world’s first, and highly successful since its mid-April launch, remains an essential step towards the safe, gradual restoration of international air services, enabling both countries to continuously refine and perfect practices to minimise the risk of further viral or bacterial transmission.
But its continued success, and that of airline operations within each country, and eventually to others, requires constant vigilance and action.
Australian biotechnology company Hygiene Labs has developed and successfully introduced an antimicrobial shield treatment, independently verified by global laboratory Eurofins to inactivate surface contaminants including the COVID-19 virus for up to 28 days, and formally listed by Australia’s medical products regulator, the Therapeutic Goods Administration, as a long-lasting treatment.
Sister company Skygard, also based in Australia, is a specialist provider of aviation maintenance, cleaning and hygiene services, and both distributes and applies the treatment, which has been introduced by aviation customers in the Asia Pacific region including international and domestic, airlines, a major VIP flight operator, and Australia’s Royal Flying Doctor Service to help protect passengers, employees, aircraft and facilities, and to reinforce existing hygiene protocols.
Hygiene Labs and Skygard are proud to support the aviation industry in dealing with the continuing challenges of COVID